{"groups":[{"description":"Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.","id":"FG000","title":"EPOCH + Concurrent Rituximab"},{"description":"Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.","id":"FG001","title":"EPOCH Followed by Rituximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"55"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"55"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}